If you miss your dasatinib dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose.
How Does It Work?
Protein kinases are proteins found in the body that control cell function, including cell growth. Dasatinib works by reducing the activity of BCR-ABL tyrosine kinase, a type of protein kinase that causes the growth of leukemia cancer cells. By reducing BCR-ABL activity, dasatinib slows down the growth of leukemia cancer cells.
Dasatinib has been shown to be effective for the treatment of chronic myeloid leukemia (CML, a type of leukemia) in clinical studies. In one of these studies, 77 percent of people given dasatinib had a "complete cytogenic response" (when cells with the abnormal chromosome that causes CML are not detectable in the blood and bone marrow), compared with 66 percent of people given Gleevec® (imatinib), another leukemia medication.
Another clinical study included people who previously took Gleevec, but stopped responding to it or did not tolerate it. In this study, 62 percent of people given dasatinib achieved a complete cytogenic response. Also, 80 percent of people had not progressed to a worse stage of leukemia after two years of treatment.
Sprycel Web site. Available at: http://www.Sprycel.com/index.jsp. Accessed October 15, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 14, 2011.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click